Summary & Overview
HCPCS J7660: Isoproterenol HCl Inhalation Solution, DME Unit-Dose
HCPCS Level II code J7660 represents compounded isoproterenol hydrochloride inhalation solution in unit-dose form, billed per milligram and intended for administration via durable medical equipment (DME). Nationally, this code is relevant for outpatient and home-based inhalation therapy where compounded bronchodilator solutions are supplied and administered through nebulizers or other aerosolizing DME. Clarity on billing for compounded inhalation drugs affects payer coverage, claims adjudication, and DME suppliers.
Key payers addressed in this summary include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for J7660—including service setting and typical use—along with the types of benchmarks and policy considerations commonly reviewed for HCPCS inhalation drug codes. The publication outlines billing and coding implications for unit-dose, per-milligram reporting of compounded inhalation products, summarizes typical payer coverage themes, and identifies areas where policy updates or documentation practices can affect reimbursement and claim consistency.
This national-level synopsis is designed for clinicians, billing professionals, DME suppliers, and policy analysts seeking a concise reference on the purpose and billing context of HCPCS Level II code J7660 and what to expect when billing compounded isoproterenol inhalation solution administered through DME.
Billing Code Overview
HCPCS Level II code J7660 describes isoproterenol hydrochloride (isoproterenol HCl) inhalation solution, a compounded product supplied in unit dose form and administered through durable medical equipment (DME). This code is reported per milligram of medication.
Service Type: Inhalation drug therapy (compounded), DME-administered
Typical Site of Service: Home or outpatient setting where DME is used for aerosolized drug delivery, including patient residences and ambulatory clinics that supply or supervise DME-based inhalation administration.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with a history of severe bronchospasm secondary to chronic obstructive pulmonary disease (COPD) presents to a durable medical equipment (DME)-equipped outpatient infusion clinic after multiple failed trials of standard bronchodilator therapy. The patient requires inhaled isoproterenol hydrochloride compounded into a unit-dose inhalation solution delivered via the patient’s DME nebulizer for short-term treatment of symptomatic bronchospasm. The DME respiratory therapist or registered nurse prepares or verifies the compounded unit-dose vial, documents lot number and milligram dose per vial, attaches the vial to the nebulizer, and supervises administration while monitoring vital signs and cardiac rhythm due to potential tachycardia or arrhythmia risk. The clinical workflow includes order entry by the prescribing clinician, pharmacy compounding and labeling per facility and USP standards, DME device check, administration with monitoring, and documentation of dose administered, route, and patient response in the medical record. Typical payors involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthCare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | General reporting when no specific modifier applies to the service |
22 |